Qiu H, Cao S, Xu R (2021) Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun 41:1037–1048

Article  Google Scholar 

Tempero MA, Malafa MP, Al-Hawary M et al (2021) Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19:439–57

Article  PubMed  CAS  Google Scholar 

Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825

Article  PubMed  CAS  Google Scholar 

Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703

Article  Google Scholar 

Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30

Article  PubMed  Google Scholar 

Groot VP, Rezaee N, Wu W et al (2018) Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Ann Surg 267:936–945

Article  PubMed  Google Scholar 

Falcomatà C, Bärthel S, Schneider G, Rad R, Schmidt-Supprian M, Saur D (2023) Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer. Cancer Discov 13:278–297

Article  PubMed  PubMed Central  Google Scholar 

Wen PY, Stein A, van den Bent M et al (2022) Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol 23:53–64

Article  PubMed  CAS  Google Scholar 

Subbiah V, Wolf J, Konda B et al (2022) Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol 23:1261–1273

Article  PubMed  CAS  Google Scholar 

Talia G, Pascal H, Michele R et al (2019) Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med 381:317–327

Article  Google Scholar 

Khan S, Budamagunta V, Zhou D (2023) Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies. Adv Cancer Res 159:145–184

Article  PubMed  CAS  Google Scholar 

Guo R, Luo J, Chang J, Rekhtman N, Arcila M, Drilon A (2020) MET-dependent solid tumours - molecular diagnosis and targeted therapy. Nat Rev Clin Oncol 17:569–587

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bradley CA, Salto-Tellez M, Laurent-Puig P et al (2017) Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nat Rev Clin Oncol 14:562–576

Article  PubMed  CAS  Google Scholar 

Halbrook CJ, Lyssiotis CA, di Magliano MP, Maitra A (2023) Pancreatic cancer: Advances and challenges. Cell 186:1729–54

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gonçalves A, Gilabert M, François E et al (2012) BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol 23:2799–2805

Article  PubMed  Google Scholar 

Rougier P, Riess H, Manges R et al (2013) Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur J Cancer 49:2633–2642

Article  PubMed  CAS  Google Scholar 

Yamaue H, Tsunoda T, Tani M et al (2015) Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Cancer Sci 106:883–890

Article  PubMed  PubMed Central  CAS  Google Scholar 

Elebiyo TC, Rotimi D, Evbuomwan IO et al (2022) Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy. Cancer Treat Res Commun 32:100620

Article  PubMed  Google Scholar 

Zhu C, Wei Y, Wei X (2019) AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer 18:153

Article  PubMed  PubMed Central  Google Scholar 

Hage C, Rausch V, Giese N et al (2013) The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death Dis 4:e627

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhen DB, Griffith KA, Ruch JM et al (2016) A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer. Invest New Drugs 34:733–739

Article  PubMed  PubMed Central  CAS  Google Scholar 

He Q, Lin Z, Wang Z et al (2020) SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET. Oncogene 39:7279–7295

Article  PubMed  Google Scholar 

Yao JF, Li XJ, Yan LK et al (2019) Role of HGF/c-Met in the treatment of colorectal cancer with liver metastasis. J Biochem Mol Toxicol 33:e22316

Article  PubMed  PubMed Central  Google Scholar 

Zhang Y, Yang Q, Zeng X et al (2021) MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING. Cancer Discov 11:2726–2737

Article  PubMed  CAS  Google Scholar 

Lindner AK, Pichler M, Thurnher M, Pichler R (2022) Targeting c-Met to Improve Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma. Eur Urol 81:1–2

Article  PubMed  CAS  Google Scholar 

Li E, Huang X, Zhang G, Liang T (2021) Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy. J Exp Clin Cancer Res 40:279

Article  PubMed  PubMed Central  CAS  Google Scholar